These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 22527355)

  • 1. Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine.
    Verbeken G; Pirnay JP; De Vos D; Jennes S; Zizi M; Lavigne R; Casteels M; Huys I
    Arch Immunol Ther Exp (Warsz); 2012 Jun; 60(3):161-72. PubMed ID: 22527355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The regulatory framework for complementary and alternative medicines in Europe].
    Knöss W; Stolte F; Reh K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):771-8. PubMed ID: 18584103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Call for a dedicated European legal framework for bacteriophage therapy.
    Verbeken G; Pirnay JP; Lavigne R; Jennes S; De Vos D; Casteels M; Huys I
    Arch Immunol Ther Exp (Warsz); 2014 Apr; 62(2):117-29. PubMed ID: 24500660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bacteriophages as antibacterial agents].
    Shasha SM; Sharon N; Inbar M
    Harefuah; 2004 Feb; 143(2):121-5, 166. PubMed ID: 15143702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacteriophages: an appraisal of their role in the treatment of bacterial infections.
    Hanlon GW
    Int J Antimicrob Agents; 2007 Aug; 30(2):118-28. PubMed ID: 17566713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Access to bacteriophage therapy: discouraging experiences from the human cell and tissue legal framework.
    Verbeken G; Huys I; De Vos D; De Coninck A; Roseeuw D; Kets E; Vanderkelen A; Draye JP; Rose T; Jennes S; Ceulemans C; Pirnay JP
    FEMS Microbiol Lett; 2016 Feb; 363(4):. PubMed ID: 26678555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacteriophages as potential new therapeutics to replace or supplement antibiotics.
    Kutateladze M; Adamia R
    Trends Biotechnol; 2010 Dec; 28(12):591-5. PubMed ID: 20810181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taking bacteriophage therapy seriously: a moral argument.
    Verbeken G; Huys I; Pirnay JP; Jennes S; Chanishvili N; Scheres J; Górski A; De Vos D; Ceulemans C
    Biomed Res Int; 2014; 2014():621316. PubMed ID: 24868534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens.
    Burrowes B; Harper DR; Anderson J; McConville M; Enright MC
    Expert Rev Anti Infect Ther; 2011 Sep; 9(9):775-85. PubMed ID: 21905786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic bacteriophages as a rescue treatment for drug-resistant infections - an in vivo studies overview.
    Kwiatek M; Parasion S; Nakonieczna A
    J Appl Microbiol; 2020 Apr; 128(4):985-1002. PubMed ID: 31778593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Procedure for the marketing authorization of an antibacterial agent].
    López Navas A; García-Escribano Ráez N; Flores Juberías Á; Suárez Gea ML
    Enferm Infecc Microbiol Clin; 2014 Oct; 32(8):529-32. PubMed ID: 25124488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phage therapy: past history and future prospects.
    Carlton RM
    Arch Immunol Ther Exp (Warsz); 1999; 47(5):267-74. PubMed ID: 10604231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory structures for gene therapy medicinal products in the European Union.
    Klug B; Celis P; Carr M; Reinhardt J
    Methods Enzymol; 2012; 507():337-54. PubMed ID: 22365782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Europe and medicines: role of the EMEA].
    Sauer F
    Ann Pharm Fr; 2000 Jul; 58(4):278-85. PubMed ID: 10915977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phage therapy: delivering on the promise.
    Harper DR; Anderson J; Enright MC
    Ther Deliv; 2011 Jul; 2(7):935-47. PubMed ID: 22833904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guidelines for Bacteriophage Product Certification.
    Fauconnier A
    Methods Mol Biol; 2018; 1693():253-268. PubMed ID: 29119445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Legal requirements for the quality of herbal substances and herbal preparations for the manufacturing of herbal medicinal products in the European union.
    Vlietinck A; Pieters L; Apers S
    Planta Med; 2009 Jun; 75(7):683-8. PubMed ID: 19204891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacteriophage Production in Compliance with Regulatory Requirements.
    Pirnay JP; Merabishvili M; Van Raemdonck H; De Vos D; Verbeken G
    Methods Mol Biol; 2018; 1693():233-252. PubMed ID: 29119444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of post-burns bacterial infections by bacteriophages, specifically ubiquitous Pseudomonas spp. notoriously resistant to antibiotics.
    Ahmad SI
    Med Hypotheses; 2002 Apr; 58(4):327-31. PubMed ID: 12027527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.